LOTTE BIOLOGICS is a CDMO established in 2022 and headquartered in Seoul, South Korea, with a biologics manufacturing site in Syracuse, New York. The Syracuse site offers drug substance manufacturing services with a total of 35,000 L of production bioreactor capacity comprising stainless-steel bioreactors, analytical QC testing laboratories, and warehouse facilities. The site is fully GMP operational with clinical and commercial capabilities. To date, the site has received 60+ approvals worldwide from the FDA, EMA, PMDA, and MFDS. In 2027, the company anticipates opening a 120,000-L mega facility in Incheon.